12:00 AM
 | 
Oct 13, 2008
 |  BC Week In Review  |  Company News  |  Deals

Alnylam, Isis, Takeda deal

Alnylam received a $20 million milestone payment from Takeda under a May 2008 deal to develop and commercialize RNAi therapeutics to treat...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >